Lee F Kuyper

Address:

6 Plowlan Pl, Durham, NC 27707

VIN:

JTDKB20U973203947

Make:

TOYOTA

Model:

PRIUS

Year:

2007

US Patent:

6369086, Apr 9, 2002

Filed:

Mar 4, 1999

Appl. No.:

09/262351

Inventors:

Stephen Thomas Davis - Durham NC
Scott Howard Dickerson - Chapel Hill NC
Philip Anthony Harris - Raleigh NC
Lee Frederick Kuyper - Durham NC
Karen Elizabeth Lackey - Hillsborough NC
Michael Joseph Luzzio - Durham NC
James Marvin Veal - Cary NC
Duncan Herrick Walker - Summit NJ

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 314439

US Classification:

514338, 5462701, 546256, 548122, 548151, 544333, 514272, 514291, 514365, 514366

Abstract:

The present invention relates generally to novel substituted oxindole compounds and compositions. Such compounds and compositions have utility as pharmacological agents in treating diseases or conditions alleviated by the inhibition or antagonism of protein kinase activated signalling pathways. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit protein tyrosine kinase and protein serine/threonine kinase inhibition, and which are useful in inhibiting tumor growth via inhibition of such kinases as well as protecting a patient undergoing chemotherapy from chemotherapy induced alopecia.

US Patent:

6387919, May 14, 2002

Filed:

Jun 6, 2000

Appl. No.:

09/486960

Inventors:

Stephen Thomas Davis - Durham NC
Scott Howard Dickerson - Chapel Hill NC
Philip Anthony Harris - Raleigh NC
Lee Frederick Kuyper - Durham NC
Michael Joseph Luzzio - Groton CT
James Marvin Veal - Apex NC
Duncan Herrick Walker - Summit NJ

Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC

International Classification:

A61K 314045

US Classification:

514291, 514366, 546 80, 548122, 548126, 548150, 548151

Abstract:

Compounds of formula (I): wherein X is N, CH, CCF , or C(C aliphatic); R is sulfonic acid, C aliphatic-sulfonyl, sulfonyl-C aliphatic, C aliphatic-sulfonyl-C aliphatic, C aliphatic-amino, R -sulfonyl, R sulfonyl-C aliphatic, R -aminosulfonyl, R -aminosulfonyl-C aliphatic, R -sulfonylamino, R -sulfonylamino-C aliphatic, aminosulfonylamino, di-C aliphatic amino, di-C aliphatic aminocarbonyl, di-C aliphatic aminosulfonyl, di-C aliphatic amino, di-C aliphatic aminocarbonyl, di-C aliphatic aminosulfonyl-C aliphatic, (R ) -Arylamino, (R ) -Arylsulfonyl, (R ) -Aryl-aminosulfonyl, (R ) -Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R is hydrogen; and further wherein R and R are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.

US Patent:

6541503, Apr 1, 2003

Filed:

Aug 8, 2001

Appl. No.:

09/924431

Inventors:

Stephen Thomas Davis - Durham NC
Scott Howard Dickerson - Chapel Hill NC
Stephen Vernon Frye - Durham NC
Philip Anthony Harris - Raleigh NC
Lee Frederick Kuyper - Durham NC
Karen Elizabeth Lackey - Hillsborough NC
Michael Joseph Luzzio - Groton CT
James Marvin Veal - Apex NC
Duncan Herrick Walker - Summit NJ

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 31429

US Classification:

514414, 514419, 514426, 548452, 548483, 548484, 5462771, 5462781, 544111

Abstract:

Compounds of formula (I): wherein X is N, CH, CCF , or C(C aliphatic); R is sulfonic acid, C aliphatic-sulfonyl, sulfonyl-C aliphatic, C aliphatic-sulfonyl-C aliphatic, C aliphatic-amino, R -sulfonyl, R sulfonyl-C aliphatic, R -aminosulfonyl, R -aminosulfonyl-C aliphatic, R -sulfonylamino, R -sulfonylamino-C aliphatic, aminosulfonylamino, di-C aliphatic amino, di-C aliphatic aminocarbonyl, di-C aliphatic aminosulfonyl, di-C aliphatic amino, di-C aliphatic aminocarbonyl, di-C aliphatic aminosulfonyl-C aliphatic, (R ) -Arylamino, (R ) -Arylsulfonyl, (R ) -Aryl-aminosulfonyl, (R ) -Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R is hydrogen; and further wherein R and R are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.

US Patent:

6624171, Sep 23, 2003

Filed:

Aug 28, 2001

Appl. No.:

09/914393

Inventors:

Philip Anthony Harris - Durham NC
Lee Frederick Kuyper - Durham NC
Karen Elizabeth Lackey - Durham NC
James Marvin Veal - Durham NC

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 31407

US Classification:

514293, 5142292, 514299, 514366, 514411, 514418, 514426, 546 79, 546 83, 546113, 546151, 548427, 548430, 548431, 548452, 548465, 548486, 548490, 544 98, 544111, 544359, 544368, 544336, 544242, 544301, 544179, 544180, 544 59, 544 61

Abstract:

Substituted aza-oxindole derivatives useful as cyclin dependent kinase 11 inhibitors, for preventing/reducing the severity of epithelial cytotoxicity side-effects (e. g. , alopecia, plantar-palmar syndrome, mucositis) induced by chemoptherapy and/or radiation therapy in a patient receiving such therapy.

US Patent:

6815439, Nov 9, 2004

Filed:

Sep 23, 2003

Appl. No.:

10/669400

Inventors:

Philip Anthony Harris - Durham NC
Lee Frederick Kuyper - Durham NC
Karen Elizabeth Lackey - Durham NC
James Marvin Veal - Durham NC

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 3133

US Classification:

514183, 5142292, 514299, 514418, 514412, 514430, 546112, 546113, 548452, 548453, 548465

Abstract:

Substituted aza-oxindole derivatives useful as cyclin dependent kinase II inhibitors, for preventing/reducing the severity of epithelial cytotoxicity side-effects (e. g. , alopecia, plantar-palmar syndrome, mucositis) induced by chemoptherapy and/or radiation therapy in a patient receiving such therapy.

US Patent:

6964977, Nov 15, 2005

Filed:

Aug 23, 2001

Appl. No.:

10/362739

Inventors:

Philip Anthony Harris - Durham NC, US
Robert N Hunter - Durham NC, US
Lee Frederick Kuyper - Durham NC, US
Karen Elizabeth Lackey - Durham NC, US
Michael Robert Peel - Durham NC, US

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K031/415

US Classification:

514387, 514383, 514364, 514418, 514339, 546196, 548131, 5482664, 5483051, 548486

Abstract:

The present invention is related to oxindole derivatives of structure (I), compositions containing the same, and methods of use and manufacture of the same. Such compounds generally are useful pharmacologically as agents in those disease states alleviated by the alteration of mitogen activated signaling pathways in general, and in particular in the inhibition or antagonism of protein kinases, which pathologically involve aberrant cellular proliferation. Such disease states include tumor growth, restenosis, atherosclerosis, pain and thrombosis. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit Trk family protein tyrosine kinase inhibition, and which are useful in cancer therapy and chronic pain indications.

US Patent:

7071217, Jul 4, 2006

Filed:

Aug 23, 2001

Appl. No.:

10/362743

Inventors:

Scott Howard Dickerson - Durham NC, US
Robert N Hunter - Durham NC, US
Lee Frederick Kuyper - Durham NC, US
Karen Elizabeth Lackey - Durham NC, US
Michael J. Luzzio - Noank CT, US

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 31/44
C07D 401/02

US Classification:

514339, 5462777, 548138, 548483, 548484, 514363, 514418

Abstract:

The present invention is related to oxindole derivatives of structure (I), compositions containing the same, and methods of use and manufacture of the same. Such compounds generally are useful pharmacologically as agents in those disease states alleviated by the alteration of mitogen activated signaling pathways in general, and in particular in the inhibition or antagonism of protein kinases, which pathologically involve aberrant cellular proliferation. Such disease states include tumor growth, restenosis, atherosclerosis, pain and thrombosis, In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit Trk family protein tyrosine kinase inhibition, and which are useful in cancer therapy and chronic pain indications.

US Patent:

7105529, Sep 12, 2006

Filed:

Nov 30, 2001

Appl. No.:

09/999331

Inventors:

Stephen Thomas Davis - Durham NC, US
Scott Howard Dickerson - Chapel Hill NC, US
Stephen Vernon Frye - Durham NC, US
Philip Anthony Harris - Raleigh NC, US
Lee Frederick Kuyper - Durham NC, US
Karen Elizabeth Lackey - Hillsborough NC, US
Michael Joseph Luzzio - Groton CT, US
James Marvin Veal - Apex NC, US
Duncan Herrick Walker - Summit NJ, US

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 31/505
A61K 31/44
A61K 31/425

US Classification:

514272, 291365, 291366

Abstract:

Compounds of formula (I): wherein X is N, CH, CCF, or C(Caliphatic); Ris sulfonic acid, Caliphatic-sulfonyl, sulfonyl-Caliphatic, Caliphatic-sulfonyl-Caliphatic, Caliphatic-amino, R-sulfonyl, Rsulfonyl-Caliphatic, R-aminosulfonyl, R-aminosulfonyl-Caliphatic, R-sulfonylamino, R-sulfonylamino-Caliphatic, aminosulfonylamino, di-Caliphatic amino, di-Caliphatic aminocarbonyl, di-Caliphatic aminosulfonyl, di-Caliphatic amino, di-Caliphatic aminocarbonyl, di-Caliphatic aminosulfonyl-Caliphatic, (R)-Arylamino, (R)-Arylsulfonyl, (R)-Aryl-aminosulfonyl, (R)-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, Ris hydrogen; and further wherein Rand Rare optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.